Congress moves to stock workplaces with overdose-reversal kits
H.R. 7479 — WORK to Save Lives Act · Filed by Bonnie Watson Coleman (D-NJ) · 16 cosponsors · Introduced Feb 10, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the Department of Labor to issue non-binding guidance to private employers on acquiring opioid overdose reversal medication (like naloxone) and offering voluntary annual training to employees on how to use it. It separately mandates that federal agencies themselves must acquire and maintain such medication and offer the same voluntary training to their employees.
Why we flagged it
The bill's operative mechanism is straightforward: it directs the Department of Labor to create guidance and regulations aimed at making opioid overdose reversal medication available in workplaces. This is a public-health intervention, not a regulatory carve-out or industry subsidy.
What the text implies
- The bill excludes the U.S. Postal Service from the private-employer guidance requirement, creating a gap in coverage for a large federal employer that handles mail and interacts with the public.
- Voluntary training language may result in low uptake if employers face no enforcement mechanism; effectiveness depends on employer buy-in and follow-through.
The full analysis lists 3 implications of this text.
Who stands to gain
pharmaceutical manufacturers of naloxone/opioid reversal medications; workplace safety training providers